Patent ID: 9713614
Date: 2017-07-25
CPC Classifications: A61K,A61P

Claim:
1. A method for the treatment of an inflammatory pulmonary disease comprising administering to a patient in need thereof a pharmaceutical composition comprising a pharmaceutical formulation including an active ingredient combination consisting of a first amount of a PDE4 inhibitor or a pharmaceutically acceptable salt thereof, and a second amount of a HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable auxiliary, wherein the PDE4 inhibitor is selected from the group consisting of ROFLUMILAST, ROFLUMILAST-N-oxide, and pharmaceutically acceptable salts of those compounds, wherein the HMG-CoA reductase inhibitor is selected from the group consisting of ROSUVASTATIN and pharmaceutically acceptable salts of ROSUVASTATIN, and wherein the active ingredient combination is present in an effective amount for the treatment of an inflammatory pulmonary disease.